Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 2/20 | 0.50 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.50 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.50 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.48 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.39 |
| ▸ | FUCA1 | P04066 | 8/20 | 0.36 |
| ▸ | GBA1 | P04062 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19969722 | 0.91 | GNAI3 (0.56) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL1433258 | 0.78 | GNAI3 (0.62) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL1932970 | 0.77 | S1PR4 (0.66) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL28243190 | 0.77 | GNAI3 (0.66) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL28207776 | 0.77 | GNAI3 (0.66) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL21367529 | 0.77 | GNAI3 (0.66) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL23139613 | 0.76 | GNAI3 (0.50) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL3959388 | 0.74 | GNAI3 (0.62) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL530708 | 0.74 | — | — | |
| SCHEMBL9801953 | 0.72 | GNAI3 (0.66) | GNAI3GNAO1GNAI1S1PR4S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1934212-B1 | 9-AZABICYCLO [3 . 3 . 1]NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS | MSD OSS BV (NL) | 2013-02-20 | — | — | EP | disclosed |
| US-7868017-B2 | 9-azabicyclo[3.3.1]nonane derivatives | N.V. ORGANON (NL) | 2011-01-11 | — | — | US | disclosed |
| EP-1934212-A1 | 9-AZABICYCLO [3 . 3 . 1]NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS | N.V. Organon (NL) | 2008-06-25 | — | — | EP | disclosed |
| US-20070112019-A1 | 9-Azabicyclo[3.3.1]nonane derivatives | N.V. ORGANON (NL) | 2007-05-17 | — | — | US | disclosed |
| WO-2007039563-A1 | 9-AZABICYCLO [3 . 3 . 1] NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS | N.V. ORGANON (NL) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112019-A1 | 9-Azabicyclo[3.3.1]nonane derivatives | AZI2, TPMT, TET3 | GNAI3 502/4885GNAO1 359/4885GNAI1 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.